GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Post-marketing, Observational, Retrospective Study to Assess the Safety of RefortrixTM (Tdap) When Administered During Pregnancy in a Maternal Immunization Program in Brazil.
Completed
- Conditions
- Diphtheria
- Interventions
- Biological: Combined diphtheria, tetanus and tricomponent acellular pertussis vaccine [Refortrix (Tdap)]
- First Posted Date
- 2016-05-02
- Last Posted Date
- 2019-10-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 2462
- Registration Number
- NCT02757950
- Locations
- 🇧🇷
GSK Investigational Site, Santo Andre, São Paulo, Brazil
Benign Prostatic Hyperplasia (BPH) Screening Tool Case Finding Study in Subjects >=50 Years
Phase 4
Completed
- Conditions
- Prostatic Hyperplasia
- Interventions
- Other: Benign prostatic enlargement (BPE)/Benign prostatic obstruction (BPO) screening toolOther: International Prostate Symptom Score (IPSS) screening tool
- First Posted Date
- 2016-05-02
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1679
- Registration Number
- NCT02757963
- Locations
- 🇪🇸
GSK Investigational Site, Valencia, Spain
A Study in Dentinal Hypersensitivity (DH) Participants to Assess the Efficacy of an Occluding Dentifrice.
Not Applicable
Completed
- Conditions
- Dentin Sensitivity
- Interventions
- Device: Experimental Oral Rinse 1Device: Experimental Oral Rinse 2Other: Placebo Oral RinseDrug: Fluoride toothpaste
- First Posted Date
- 2016-04-27
- Last Posted Date
- 2018-08-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 240
- Registration Number
- NCT02753075
- Locations
- 🇺🇸
GSK Investigational Site, Fort Wayne, Indiana, United States
Impact of Long Term Management of Dentine Hypersensitivity (DH) With a Daily Use Anti-sensitivity Toothpaste on the Quality of Life Related to Oral Health
- First Posted Date
- 2016-04-27
- Last Posted Date
- 2018-08-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 75
- Registration Number
- NCT02752958
- Locations
- 🇬🇧
GSK Investigational Site, Widnes, Cheshire, United Kingdom
Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A) in Healthy Women
Phase 2
Completed
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Biological: RSV vaccine GSK3003891ABiological: Boostrix
- First Posted Date
- 2016-04-27
- Last Posted Date
- 2018-06-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 102
- Registration Number
- NCT02753413
- Locations
- 🇧🇪
GSK Investigational Site, Wilrijk, Belgium
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Intravenous Single Dose and Repeat Dose of GSK3342830
Phase 1
Terminated
- Conditions
- Infections, Bacterial
- Interventions
- Drug: GSK3342830Drug: Placebo
- First Posted Date
- 2016-04-26
- Last Posted Date
- 2018-09-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 62
- Registration Number
- NCT02751424
- Locations
- 🇦🇺
GSK Investigational Site, Adelaide, South Australia, Australia
Potential of Stannous Fluoride Toothpaste to Reduce Gum Disease
Not Applicable
Completed
- Conditions
- Gingivitis
- Interventions
- First Posted Date
- 2016-04-26
- Last Posted Date
- 2017-10-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 253
- Registration Number
- NCT02750943
- Locations
- 🇺🇸
GSK Investigational Site, Las Vegas, Nevada, United States
A Study to Assess the Effects of Dissolution Profile on the Pharmacokinetics of Single Oral Doses of Tafenoquine Tablets and Tafenoquine Stable Isotope Labelled Solution
Phase 1
Completed
- Conditions
- Malaria, Vivax
- Interventions
- First Posted Date
- 2016-04-26
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 14
- Registration Number
- NCT02751294
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States
Efficacy of Three Toothpastes Using an in Situ Caries Model
Not Applicable
Completed
- Conditions
- Dental Caries
- Interventions
- Drug: 1150ppm FDrug: 0.3%ZnCl2, 0.5% sodium citrate, 1150ppm FOther: 0 ppm FDrug: 0.425 % w/w phytate,1150ppm FDrug: 0.85 % w/w phytate,1150ppm FDrug: 0.85 % w/w phytate,0.3%ZnCl2 0.5% sodium citrate, 1150ppm F
- First Posted Date
- 2016-04-26
- Last Posted Date
- 2017-10-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 58
- Registration Number
- NCT02751320
- Locations
- 🇺🇸
GSK Investigational Site, Indianapolis, Indiana, United States
The Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity(DH)
Not Applicable
Completed
- Conditions
- Dentin Sensitivity
- Interventions
- Device: Stannous Fluoride dentificeOther: Sodium Monofluorophosphate dentifrice
- First Posted Date
- 2016-04-26
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 263
- Registration Number
- NCT02751450
- Locations
- 🇬🇧
GSK Investigational Site, Bristol, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath